Our Blog

FDA request more data for Starpharma’s infection gel approval

28 Dec 2018 – Biotech company Starpharma (ASX:SPL) has received advice from the US Food and Drug Administration that it will require more clinical data prior to approving VivaGel® BV for treatment of bacterial vaginosis.


Source: Finance News Network

Share this post